Filing Flows › Teva Pharmaceutical Industries (TEVA) › Capital expenditures
Teva Pharmaceutical Industries (TEVA) capital expenditures by quarter
Teva Pharmaceutical Industries' capital expenditures were $120M in Q3 2026 (third quarter 2026), +15% from Q2 2026. Over the last 5 quarters it ranged from $96.0M (Q2 2025) to $142M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $120M | +15% | -12% |
| Q2 2026 | $104M | -27% | +8% |
| Q4 2025 | $142M | +4% | — |
| Q3 2025 | $136M | +42% | — |
| Q2 2025 | $96.0M | — | — |
Q3 2026 at a glance
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
What is Teva Pharmaceutical Industries' capital expenditures?
Teva Pharmaceutical Industries' capital expenditures were $120M in Q3 2026 (third quarter 2026), +15% from Q2 2026.
How has Teva Pharmaceutical Industries' capital expenditures changed?
Over the last 5 quarters it ranged from $96.0M (Q2 2025) to $142M (Q4 2025).
Q3 2026 results → · How Teva Pharmaceutical Industries makes money →